Relapsing-Remitting Multiple Sclerosis (RRMS)NCT05245344
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study
An observational study of Relapsing-Remitting Multiple Sclerosis (RRMS) and Neuromyelitis Optica, run by Neuromed IRCCS at 3 sites in Italy.
Trial summary
This is a prospective non interventional study including patients with Relapsing-Remitting Multiple Sclerosis (RRMS) or with Neuromyelitis Optica Spectrum Disorders (NMOSD) and healthy subjects, who are enrolled within the routinely programmed clinical examinations at the IRCCS Neuromed (Pozzilli, Italy), IRCCS… Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Relapsing-Remitting Multiple Sclerosis (RRMS), Neuromyelitis Optica, Healthy
- What is being tested?
- Peripheral blood withdrawal
- Type of treatment
- Surgery or procedure
- How many people
- 154 participants
- Where
- 3 sitesItaly
- Study dates
- 1 Apr 2022to 31 Oct 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: This is a prospective non interventional study with MS patients enrolled within the routinely programmed clinical examinations at the IRCCS NeuromedPozzilli, IRCCS polyclinic hospital San Martino (Genoa, Italy), Sant'Andrea Hospital - University of Rome La Sapienza (Rome, Italy). Study population: Approximately 72 Relapsing-Remitting Multiple Sclerosis (RRMS - naïve or after 3 months wash out from DMT patients; 10 Neuromyelitis Optica Spectrum Disorders patients (NMOSD); 72 healthy subjects (HD) will be recruited from the hospitals involved in the study.
Who may be able to join
- Main inclusion criteria of patients with RRMS:
- Relapsing-remitting MS, as diagnosed by the revised 2010 McDonald Criteria
- EDSS score ≤ 5.5;
- Age between 18 and 55 years (exclusive);
- No disease modifying therapies for at least 3 months or treatment naïve;
- No corticosteroid administration in the previous month;
Show all 20Show fewer
- Disease duration <10 years;
- Ability to provide written informed consent.
- For the estimation of radiological variables, brain and spinal cord MRI will be performed according to clinical practice and lesions will be classified as symptomatic or asymptomatic if they were associated with clinical relapse or not.
- Patient groups will be matched by gender, age, ethnicity and MS duration.
- Main inclusion criteria of patients with NMOSD (Wingerchuk et al., 2015):
- Positive test for Aquaporin 4 IgG;
- Age between 18 and 55 years (exclusive);
- no immunosuppressive therapies for at least 3 months or treatment naïve
- no corticosteroid administration in the previous month
- disease duration <10 years
- Ability to provide written informed consent
- Healthy subjects
- Age between 18 and 55 years (exclusive), matched by gender, age and ethnicity towards the MS groups.
- Ability to provide written informed consent
Who cannot join
- Adverse effects to MRI imaging with i.v. gadolinium;
- Blood count basal alteration;
- Clinically significant medical condition other than MS, including latent infections (e.g. tuberculosis, viral hepatitis, HIV/AIDS) that might confound the results of the study.
Trial locations and contacts
3 sites in 1 country.
Italy3 sites
IRCCS Ospedale Policlinico San Martino
Genova
Antonio Uccelli, PhD, direzione.scientifica@hsanmartino.it
Tiziana Vigo, PhD, tiziana.vigo@hsanmartino.it
IRCCS INM-Neuromed
Pozzilli, Isernia, 86077
Stefania Passarelli, +39 0865915217, direzionescientifica@neuromed.it
Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome
Roma
Marco Salvetti, PhD, 0039-0633775829, marco.salvetti@uniroma1.it
About this study
This is a prospective non interventional study including patients with Relapsing-Remitting Multiple Sclerosis (RRMS) or with Neuromyelitis Optica Spectrum Disorders (NMOSD) and healthy subjects, who are enrolled within the routinely programmed clinical examinations at the IRCCS Neuromed (Pozzilli, Italy), IRCCS Polyclinic Hospital San Martino (Genoa, Italy) and Sant'Andrea Hospital - University of Rome La Sapienza (Rome, Italy).
Specifically, the study investigates how ozanimod may contrast neurodegenerative mechanisms triggered by both arms of the adaptive immune response (T and B cells) and by their suboptimal regulation in MS. Overall, the project aims at assessing by in vitro experiments (there will be no patients on treatment with ozanimod and the drug will be only used in vitro):
Read more
AIM1: ozanimod ability to modulate the synaptotoxic effect of T-cells derived from patients with MS relapse in a MS-chimeric ex-vivo model and to identify possible mediators (IRCCS Neuromed-Pozzilli, in collaboration with Synaptic Immunopathology Laboratory Dep. Systems Medicine, Tor Vergata University of Rome); AIM2: ozanimod ability to reduce the cytokine-mediated breakdown of the BBB and the migration of the here studied immune cells through ex vivo models of BBB (IRCCS Polyclinic Hospital San Martino); AIM3: ozanimod ability to affect the migration properties of Epstein Barr virus (EBV) infected B cells in MS (Sant'Andrea Hospital); AIM4: ozanimod ability to modulate the number and/or function of regulatory T cells (Treg), a lymphocyte population playing a key role in the control of pathogenic adaptive immune responses (Treg Cell Laboratory, Università degli Studi di Napoli "Federico II", Naples, Italy, receiving blood samples from Neuromed Hospital and Sant'Andrea Hospital; not recruiting unit).
The work of the four labs is conceptually and operationally integrated: the labs at IRCCS Neuromed-Pozzilli/Tor Vergata University (Aim1) and at Polyclinic Hospital San Martino (Aim2) will investigate the effects of ozanimod on well-known mechanisms of damage in MS, inflammatory synaptopathy and BBB damage and immune cell migration. The lab at Sant'Andrea Hospital (Aim3), will verify whether B cells infected by different EBV genotypes are involved in BBB migration, and how ozanimod may interfere with this mechanism. The Treg Cell Laboratory (Aim4) will investigate whether ozanimod can also act "upstream" of these mechanisms by regulating the adaptive immune response.
Read the detailed description
Multiple sclerosis (MS) is a multifactorial and complex disease with several and tangled pathophysiological mechanisms, responsible for the inflammatory and neurodegenerative damage. Therapies targeting inflammatory pathways have brought substantial progress in the treatment of relapsing-remitting MS. Disappointingly, the impact of these treatments on neurodegeneration is limited. To tackle the complexity of the problem, combination therapies may be necessary. However, safety, tolerability and cost issues have so far limited this option. Single therapies that target at once inflammation and neurodegeneration are an appealing alternative. However, a comprehensive understanding of their effects is essential to maximize their impact.
Ozanimod is a molecule that targets simultaneously inflammation and neurodegeneration. Its impact on the latter is less well understood. The drug produces its effects by acting on two (S1P1 and S1P5) of the five sphingosine-1-phosphate G protein-coupled receptor subtypes. While the molecular targets of the drug are precisely defined, much remains to be learned about the many biological effects that may follow receptors' modulation.
A collaborative and integrated approach is proposed to deepen our understanding of ozanimod's effects on the complex pathophysiology of MS.
The research will focus on crucial aspects for MS biology. Specifically, it will be investigated how ozanimod may contrast neurodegenerative mechanisms triggered by both arms of the adaptive immune response (T and B cells) and by their suboptimal regulation in MS. Overall, the project aims at investigating:
AIM1: ozanimod ability to modulate the synaptotoxic effect of T-cells derived from active MS patients in a MS-chimeric ex-vivo model and to identify possible mediators (IRCCS Neuromed-Pozzilli, in collaboration with Synaptic Immunopathology Laboratory Dep. Systems Medicine, Tor Vergata University of Rome). Inflammatory synaptopathy, namely synapse loss and synaptic dysfunction, is emerging as an important hallmark of grey matter pathology in MS and its mouse model experimental autoimmune encephalomyelitis (EAE). In the past years, evidence has been provided of a direct role of T cell, derived from MS patients or EAE mice, in inducing glutamate-mediated excitotoxicity, a prominent form of synaptopathy detected in the MS/EAE brain. Notably, several lines of evidence indicate that limiting glutamate-excitotoxicity is an attractive therapeutic strategy to treat MS.
Recently, the modulatory effects of ozanimod on inflammatory glutamate-mediated excitotoxicity was investigated and the different involvement of sphingosine receptor subtypes (S1P1 and S1P5) were evaluated in the EAE model. Two main results emerged: first, the S1P1/S1P5 modulator ozanimod has central neuroprotective effects likely mediated by an action on microglia cells and infiltrating lymphocytes, resulting in a reduced release of proinflammatory cytokines, the main players of inflammatory synaptopathy. Second, the central delivery of a selective S1P1 modulator showed neuroprotective effects, in terms of both EAE clinical score and inflammatory synaptopathy, suggesting a primary involvement of this receptor subtype in ozanimod- induced neuroprotection also in MS.
In the present project, the MS chimeric ex-vivo model recently developed in Tor Vergata University' lab, will be used. T cells isolated from active relapsing remitting MS patients but not from non-active (naMS) and healthy subject (HS), induced an increase of the spontaneous glutamatergic currents, reminiscent of the alterations induced by EAE T cells.
In this specific aim of the project, the following aspect will be assessed: i) to investigate if ozanimod is able to modulate the synaptotoxic effect of T dell derived from active MS patients in the MS-chimeric ex-vivo model and ii) to identify sphingosine receptor subtypes and iii) soluble molecules potentially involved.
A role for ozanimod in dampening excitotoxic damage caused by synaptotoxic T-cell circulating in the MS brain, independently of a prevention of T cell trafficking, is expected to be revealed.
AIM2: ozanimod ability to reduce the cytokine-mediated breakdown of the BBB and the migration of the here studied immune cells through ex vivo models of BBB (IRCCS Polyclinic Hospital San Martino). B and T lymphocytes, and NK cells are involved in MS pathogenesis (Lassmann, 2019). They differentially use S1P1 and S1P5 receptors to regulate their traffic across secondary lymphoid tissues, and to enter the CNS through the BBB (Sallusto et al., 2012). In turn, these receptors are important in maintaining the integrity and in restoring the function of BBB (Chun 2021).
Modulators of S1P1 and S1P5 receptors are widely used to treat MS, but their mode of action is only partially known due to the complex downstream effects of the combined interactions among receptors localized at the membrane surfaces of immune cells and at the endothelial cells and podocytes of the BBB. These modulating features have been mainly studied for fingolimod, the first drug of this class used in MS, whereas ozanimod's mechanisms of action need in-depth investigations. Indeed, this drug has chemical structure different from that of fingolimod, a binding restricted to S1P1 and S1P5 receptors vs S1P1, S1P3, S1P4 and S1P5 of fingolimod, different pharmacokinetics, and shorter time of elimination half-life (Chun et al., 2021).
The purpose of this specific aim is to evaluate, in ex vivo models of the human BBB exploited through transwell-based systems and organoids, the effects of ozanimod on: i) maintaining of BBB integrity in a context of cytokine-mediated barrier breakdown; ii) impairing the migration of T cells and NK cells across BBB.
The ex-vivo exposure of peripheral blood mononuclear cells (PBMCs) from MS patients to ozanimod is expected to reduce the damage of the BBB mediated by pro-inflammatory cytokines, as well as to mitigate ability of these immune cells across the BBB. PBMCs of patients with NMOSDs will be also used as inflammatory controls, since in these disorders Th17 cells have a major pathogenetic role, together with the BBB-targeting AQP-4 antibodies.
AIM3: ozanimod ability to affect the migration properties of Epstein-Barr virus (EBV) infected B cells in MS (Sant'Andrea Hospital).
In the general population, the memory subset of B lymphocytes, proved to be decreased during therapy with S1P receptors modulators, is the one that selectively harbors EBV as a latently infecting agent. Several studies on EBV genotypes demonstrated an association of specific Epstein- Barr nuclear antigen 2 (EBNA2) gene variants with MS. EBNA2 acts as a transactivator on both viral and cellular gene promoters/enhancers by obligatory interactions with host cell transcription factors. Taking into consideration the complex interplay between EBNA2 and cellular components, it is likely that EBNA2 variants may affect the processes of early infection and participate in the dysregulated virus-host interactions in MS. Also, MS-associated EBNA2 variants seem to interfere with B cell migration and maturation within germinal centers. Despite the presence of EBV infection in the MS brain is controversial, some observations support evidence of an intrathecal reactivation and virus-driven immunopathogenic response in MS. The hypothesis of this specific aim is that ozanimod can have immunomodulatory effects on B cells and EBV infected cells in a MS context. As already mentioned, ozanimod is a potent S1P1R modulator, that inhibits the egress of lymphocytes from lymphoid tissues. B cells and lymphoblastoid cell lines [spontaneously outgrowing (spLCLs) or in vitro infected with the EBV laboratory strain B95.8 (95.8LCLs)], will be used to study how EBV infection affects migration capacity and how this capacity is affected by ozanimod.
Specifically, the following aspect will be investigated: i) the migration properties of B cells, spLCLs and B95.8LCLs from MS patients and age- and sex-matched healthy donors (HD); ii) if ozanimod is able to modulate the migration properties of the above cells from patients and HD.
The knowledge of ozanimod influence on B cells and EBV-infected B cells migration through lymphoid organs and even in the brain, will be importantly improved by this research.
AIM4: ozanimod ability to modulate the number and/or function of regulatory T cells (Treg), a lymphocyte population playing a key role in the control of autoimmune responses (Treg Cell Laboratory, Università degli Studi di Napoli "Federico II", Naples, Italy, receiving blood samples from Neuromed Hospital and Sant'Andrea Hospital; not recruiting unit). Intracellular metabolic pathways are able to control the induction and function of different immune cellular subsets, indeed glycolysis is indispensable for the generation of human iTreg cells from Tconv cells. In addition, a glycolytic defect during the activation of Tconv cells in MS and T1D subjects, was associated with a reduced induction and suppressive function of iTreg cells in these patients suggesting a defective function of iTreg cells during autoimmunity. The effect of ozanimod on the cellular metabolic profile of T lymphocytes and of iTreg cells will be investigated. In particular, this specific aim will evaluate i) the capacity of ozanimod to affect T cell and iTreg cell function/activity (activation, proliferation, suppression, Foxp3 induction) and ii) the metabolic asset of circulating T cell populations (ie. measurement of glycolysis and oxidative phosphorylation) purified from healthy subjects and MS patients.
Ozanimod is expected to be able to control immunometabolism of Tconv and iTreg cells in RRMS patients. This aim will also assess whether ozanimod is able to modify the induction of iTreg cells in healthy controls and RRMS patients.
- Being tested
- Peripheral blood withdrawal
- Keywords
- in vitro ozanimod treatment, T cells, Treg cells, NK cells, B cells, T-cell-mediated synaptotoxicy, cytokine-mediated breakdown of the Blood Brain Barrier, Epstein-Barr virus (EBV) infected B cells
- Medical subject headings
- Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica, Epstein-Barr Virus Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Peripheral blood withdrawalProcedure or surgery
25 ml of blood for T cell isolation or 40 ml of blood for B cell isolation will be obtained following informed consent as approved by the ethical committees of the MS centers.
| Study group | Role | What they receive |
|---|---|---|
| Patients with RRMS (untreated) | * Relapsing-remitting MS, as diagnosed by the revised 2010 McDonald Criteria;
* EDSS score ≤ 5.5;
* Age between 18 and 55 years (exclusive);
* no disease modifying therapies for at least 3 months or treatment naïve;
* no corticosteroid administration in the previous month;
* disease duration <10 years;
* Ability to provide written informed consent. Receives: Procedure: Peripheral blood withdrawal | |
| Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD) | Main inclusion criteria of NMOSD patients (Wingerchuk et al., 2015):
* Positive test for Aquaporin 4 IgG;
* Age between 18 and 55 years (exclusive);
* no immunosuppressive therapies for at least 3 months or treatment naïve.
* no corticosteroid administration in the previous month
* disease duration <10 years
* Ability to provide written informed consent Receives: Procedure: Peripheral blood withdrawal | |
| Healthy subjects (HD) | * Age between 18 and 55 years (exclusive), matched by gender, age and ethnicity towards the MS groups.
* Ability to provide written informed consent. Receives: Procedure: Peripheral blood withdrawal |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the potential anti-synaptotoxic effect of ozanimod on electrophysiological kinetics in the MS chimeric model
1.1.1. T cells will be isolated from the peripheral blood of naïve active RRMS patients and will be reated in culture with ozanimod (1000 nM) or vehicle for 24 h. After treatment, T cells will be incubated on corticostriatal slices derived from healthy mice and electrophysiological recording will be performed to measure:
- kinetics of the spontaneous synaptic transmission (half width, decay time and rise time, in ms);
The same experiments will be performed by using cell treated with S1P1 and S1P5 selective agonists.
The primary endpoint will be the comparison of electrophysiological parameters between ozanimod and vehicle conditions, to evaluate a potential beneficial effect of ozanimod on the synaptic alterations induced by MS lymphocytes.
Measured: 18 months
To evaluate the potential anti-synaptotoxic effect of ozanimod on electrophysiological frequency in the MS chimeric model
1.1.2. T cells will be isolated from the peripheral blood of naïve active RRMS patients and will be reated in culture with ozanimod (1000 nM) or vehicle for 24 h. After treatment, T cells will be incubated on corticostriatal slices derived from healthy mice and electrophysiological recording will be performed to measure:
- frequency of the spontaneous synaptic transmission (in Hz);
The same experiments will be performed by using cell treated with S1P1 and S1P5 selective agonists.
The primary endpoint will be the comparison of electrophysiological parameters between ozanimod and vehicle conditions, to evaluate a potential beneficial effect of ozanimod on the synaptic alterations induced by MS lymphocytes.
Measured: 18 months
To evaluate the potential anti-synaptotoxic effect of ozanimod on electrophysiological amplitude in the MS chimeric model
1.1.3. T cells will be isolated from the peripheral blood of naïve active RRMS patients and will be reated in culture with ozanimod (1000 nM) or vehicle for 24 h. After treatment, T cells will be incubated on corticostriatal slices derived from healthy mice and electrophysiological recording will be performed to measure:
- amplitude of the spontaneous synaptic transmission (in pA).
The same experiments will be performed by using cell treated with S1P1 and S1P5 selective agonists.
The primary endpoint will be the comparison of electrophysiological parameters between ozanimod and vehicle conditions, to evaluate a potential beneficial effect of ozanimod on the synaptic alterations induced by MS lymphocytes.
Measured: 18 months
To asses the ability of ozanimod to reduce the breakdown of the ex vivo model of BBB (BBB integrity).
2.1. The impact on the integrity of BBB will be assessed for T and NK cells isolated from naive MS patients, and exposed or not ex-vivo to ozanimod.
Differences in the expression of the tight junction proteins as Claudin-5, Occludin, Zonula Occludens-1 (fold change) upon exposure of BBB models to immune cells from MS patients, treated or not ex vivo with ozanimod, will be evaluated.
The primary endpoint will be the comparison of BBB integrity, matching the results from ozanimod stimulated vs ozanimod unstimulated cells taken from each patient.
Measured: 18 months
To asses the ability of ozanimod to reduce the cytokine-mediated permeability of the ex vivo model of BBB.
2.2. The impact on the migration ability across the BBB will be assessed for T and NK cells isolated from naive MS patients, and exposed or not ex-vivo to ozanimod.
Differences in the migration across ex vivo models of BBB of immune cells isolated from MS patients after incubation with ozanimod, will be evaluated (dye fluorescencent signal).
The primary endpoint will be the comparison of BBB permeability to T and NK cells, matching the results from ozanimod stimulated vs ozanimod unstimulated cells taken from each patient.
Measured: 18 months
To evaluate the migration properties of B cells, spLCLs (with 1.2 and with 1.3 viral alleles) and B95.8LCLs isolated from peripheral blood of (untreated) RRMS and HD.
- B cells and LCLs will be cultured in the presence of different drug concentrations and transwell migration assays will be performed to evaluate their ability to migrate through a membrane. At least 5 LCLs and related B cells will be tested for each EBNA2 alleles.
Specifically, this aim will investigate: The migration properties of B cells, spLCLs and B95.8LCLs from MS patients and age- and sex-matched HD, and if ozanimod is able to modulate the migration properties of the above cells from patients and HD.
The primary endpoint will be the comparison of the migratory capacity (sphingosine- and chemokine-driven) of EBV-infected B cells compared to non-infected cells; whether different viral genotypes modify this capacity; whether and how the above properties differ between patients and controls; whether and how ozanimod affects the above properties.
Measured: 18 months
To evaluate the effect of ozanimod on the proliferation of Treg cells
4.1. It has been demonstrated that human CD4+CD25- Tconv cells isolated from PBMC of human subjects and activated in vitro in the presence of low-TCR engagement, acquire a suppressive phenotype and generate highly suppressive human iTreg cells.
Therefore, in order to evaluate the effect of ozanimod on the induction of iTreg, Tconv cells will be isolated from healthy subjects and RRMS patients and after 36 h culture in the presence of ozanimod or vehicle, activated CD4+CD25- T cells will be FACS-sorted and will be analyzed for their proliferative potential (Ki67 fluorescence).
The primary endpoint will be the comparison of iTreg cell proliferation between Tconv cell stimulated in the presence or not of ozanimod.
Measured: 18 months
To evaluate the effect of ozanimod on metabolic asset of Treg cells.
4.2. After Tconv cells isolation from healthy subjects and RRMS patients and 36 h culture in the presence of ozanimod or vehicle, activated CD4+CD25- T cells will be FACS-sorted and will be analyzed for metabolic asset.
The effect of ozanimod on the metabolic asset of iTreg will be evaluated by assessing p-S6 fluorescence.
The primary endpoint will be the comparison of iTreg cell metabolic asset between Tconv cell stimulated in the presence or not of ozanimod.
Measured: 18 months
To evaluate the effect of ozanimod on the function of Treg cells.
4.3. After Tconv cells isolation from healthy subjects and RRMS patients and 36 h culture in the presence of ozanimod or vehicle, activated CD4+CD25- T cells will be FACS-sorted and will be analyzed for their function.
The effect of ozanimod on the induction of iTreg will be evaluated by assessing the expression levels of the two major FoxP3 splicing forms, one containing (FoxP3E2) and the other lacking (FoxP3∆2) the exon 2.
The primary endpoint will be the comparison of iTreg cell function between Tconv cell stimulated in the presence or not of ozanimod.
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2022
- Study start1 Apr 2022 (estimated)
- Primary completion30 Jun 2023 (estimated)
- Study completion31 Oct 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (32)Papers the sponsor has linked to this study.
- Other trials for Relapsing-Remitting Multiple Sclerosis (RRMS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 154 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Neuromed IRCCS
- Sponsor type
- University, hospital or other
- Collaborators
- University of Rome Tor Vergata
- Responsible party
- Principal investigator, Fabio Buttari, Neuromed IRCCS
- Investigators
- Fabio Buttari, PhD, Principal investigator, IRCCS Neuromed, Pozzilli, Isernia Italy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05245344
- Sponsor's protocol ID
- MulticOZ-MS
- Status last verified
- Feb 2022
- First submitted
- 30 Dec 2021
- Last updated
- 17 Feb 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Musella A, Gentile A, Guadalupi L, Rizzo FR, De Vito F, Fresegna D, Bruno A, Dolcetti E, Vanni V, Vitiello L, Bullitta S, Sanna K, Caioli S, Balletta S, Nencini M, Buttari F, Stampanoni Bassi M, Centonze D, Mandolesi G. Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis. Cells. 2020 May 22;9(5):1290. doi: 10.3390/cells9051290.
PubMed 32455907De Rosa V, Galgani M, Porcellini A, Colamatteo A, Santopaolo M, Zuchegna C, Romano A, De Simone S, Procaccini C, La Rocca C, Carrieri PB, Maniscalco GT, Salvetti M, Buscarinu MC, Franzese A, Mozzillo E, La Cava A, Matarese G. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat Immunol. 2015 Nov;16(11):1174-84. doi: 10.1038/ni.3269. Epub 2015 Sep 28.
PubMed 26414764Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, Fornasiero A, D'Erchia AM, Buscarinu MC, Agliardi C, Annibali V, Serafini B, Rosicarelli B, Romano S, Angelini DF, Ricigliano VA, Buttari F, Battistini L, Centonze D, Guerini FR, D'Alfonso S, Pesole G, Salvetti M, Ristori G. Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology. 2015 Mar 31;84(13):1362-8. doi: 10.1212/WNL.0000000000001420. Epub 2015 Mar 4.
PubMed 25740864Agasing AM, Wu Q, Khatri B, Borisow N, Ruprecht K, Brandt AU, Gawde S, Kumar G, Quinn JL, Ko RM, Mao-Draayer Y, Lessard CJ, Paul F, Axtell RC. Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nat Commun. 2020 Jun 5;11(1):2856. doi: 10.1038/s41467-020-16625-7.
PubMed 32503977Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F, Battistini L. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9(4):e1003220. doi: 10.1371/journal.ppat.1003220. Epub 2013 Apr 11.
PubMed 23592979Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron. 2018 Feb 21;97(4):742-768. doi: 10.1016/j.neuron.2018.01.021.
PubMed 29470968Bergmann S, Lawler SE, Qu Y, Fadzen CM, Wolfe JM, Regan MS, Pentelute BL, Agar NYR, Cho CF. Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics. Nat Protoc. 2018 Dec;13(12):2827-2843. doi: 10.1038/s41596-018-0066-x.
PubMed 30382243Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, Musella A, D'Amelio M, Cavallucci V, Martorana A, Bergamaschi A, Cencioni MT, Diamantini A, Butti E, Comi G, Bernardi G, Cecconi F, Battistini L, Furlan R, Martino G. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci. 2009 Mar 18;29(11):3442-52. doi: 10.1523/JNEUROSCI.5804-08.2009.
PubMed 19295150Chiara M, Manzari C, Lionetti C, Mechelli R, Anastasiadou E, Chiara Buscarinu M, Ristori G, Salvetti M, Picardi E, D'Erchia AM, Pesole G, Horner DS. Geographic Population Structure in Epstein-Barr Virus Revealed by Comparative Genomics. Genome Biol Evol. 2016 Dec 14;8(11):3284-3291. doi: 10.1093/gbe/evw226.
PubMed 27635051Chun J, Giovannoni G, Hunter SF. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. Drugs. 2021 Feb;81(2):207-231. doi: 10.1007/s40265-020-01431-8.
PubMed 33289881Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7.
PubMed 18970977Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015 Sep 15;15(9):545-58. doi: 10.1038/nri3871. Epub 2015 Aug 7.
PubMed 26250739Gentile A, De Vito F, Fresegna D, Rizzo FR, Bullitta S, Guadalupi L, Vanni V, Buttari F, Stampanoni Bassi M, Leuti A, Chiurchiu V, Marfia GA, Mandolesi G, Centonze D, Musella A. Peripheral T cells from multiple sclerosis patients trigger synaptotoxic alterations in central neurons. Neuropathol Appl Neurobiol. 2020 Feb;46(2):160-170. doi: 10.1111/nan.12569. Epub 2019 Jun 17.
PubMed 31125471Harris S, Tran JQ, Southworth H, Spencer CM, Cree BAC, Zamvil SS. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 31;7(5):e839. doi: 10.1212/NXI.0000000000000839. Print 2020 Sep.
PubMed 32737072Hwang IY, Park C, Harrison K, Kehrl JH. Biased S1PR1 Signaling in B Cells Subverts Responses to Homeostatic Chemokines, Severely Disorganizing Lymphoid Organ Architecture. J Immunol. 2019 Nov 1;203(9):2401-2414. doi: 10.4049/jimmunol.1900678. Epub 2019 Sep 23.
PubMed 31548329
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study
- ClinicalTrials.gov ID
- NCT05245344
- Acronym / sponsor ID
- MulticOZ-MS
- Keywords
- in vitro ozanimod treatment, T cells, Treg cells, NK cells, B cells, T-cell-mediated synaptotoxicy, cytokine-mediated breakdown of the Blood Brain Barrier, Epstein-Barr virus (EBV) infected B cells
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 154 participants (estimated)
- Lead sponsor
- Neuromed IRCCSUniversity, hospital or other
- Collaborators
- University of Rome Tor Vergata
- Study start
- 1 Apr 2022 (estimated)
- Primary completion
- 30 Jun 2023 (estimated)
- Study completion
- 31 Oct 2023 (estimated)
- First posted
- 17 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective non interventional study including patients with Relapsing-Remitting Multiple Sclerosis (RRMS) or with Neuromyelitis Optica Spectrum Disorders (NMOSD) and healthy subjects, who are enrolled within the routinely programmed clinical examinations at the IRCCS Neuromed (Pozzilli, Italy), IRCCS Polyclinic Hospital San Martino (Genoa, Italy) and Sant'Andrea Hospital - University of Rome La Sapienza (Rome, Italy).
Specifically, the study investigates how ozanimod may contrast neurodegenerative mechanisms triggered by both arms of the adaptive immune response (T and B cells) and by their suboptimal regulation in MS. Overall, the project aims at assessing by in vitro experiments (there will be no patients on treatment with ozanimod and the drug will be only used in vitro):
AIM1: ozanimod ability to modulate the synaptotoxic effect of T-cells derived from patients with MS relapse in a MS-chimeric ex-vivo model and to identify possible mediators (IRCCS Neuromed-Pozzilli, in collaboration with Synaptic Immunopathology Laboratory Dep. Systems Medicine, Tor Vergata University of Rome); AIM2: ozanimod ability to reduce the cytokine-mediated breakdown of the BBB and the migration of the here studied immune cells through ex vivo models of BBB (IRCCS Polyclinic Hospital San Martino); AIM3: ozanimod ability to affect the migration properties of Epstein Barr virus (EBV) infected B cells in MS (Sant'Andrea Hospital); AIM4: ozanimod ability to modulate the number and/or function of regulatory T cells (Treg), a lymphocyte population playing a key role in the control of pathogenic adaptive immune responses (Treg Cell Laboratory, Università degli Studi di Napoli "Federico II", Naples, Italy, receiving blood samples from Neuromed Hospital and Sant'Andrea Hospital; not recruiting unit).
The work of the four labs is conceptually and operationally integrated: the labs at IRCCS Neuromed-Pozzilli/Tor Vergata University (Aim1) and at Polyclinic Hospital San Martino (Aim2) will investigate the effects of ozanimod on well-known mechanisms of damage in MS, inflammatory synaptopathy and BBB damage and immune cell migration. The lab at Sant'Andrea Hospital (Aim3), will verify whether B cells infected by different EBV genotypes are involved in BBB migration, and how ozanimod may interfere with this mechanism. The Treg Cell Laboratory (Aim4) will investigate whether ozanimod can also act "upstream" of these mechanisms by regulating the adaptive immune response.
Detailed description
Multiple sclerosis (MS) is a multifactorial and complex disease with several and tangled pathophysiological mechanisms, responsible for the inflammatory and neurodegenerative damage. Therapies targeting inflammatory pathways have brought substantial progress in the treatment of relapsing-remitting MS. Disappointingly, the impact of these treatments on neurodegeneration is limited. To tackle the complexity of the problem, combination therapies may be necessary. However, safety, tolerability and cost issues have so far limited this option. Single therapies that target at once inflammation and neurodegeneration are an appealing alternative. However, a comprehensive understanding of their effects is essential to maximize their impact.
Ozanimod is a molecule that targets simultaneously inflammation and neurodegeneration. Its impact on the latter is less well understood. The drug produces its effects by acting on two (S1P1 and S1P5) of the five sphingosine-1-phosphate G protein-coupled receptor subtypes. While the molecular targets of the drug are precisely defined, much remains to be learned about the many biological effects that may follow receptors' modulation.
A collaborative and integrated approach is proposed to deepen our understanding of ozanimod's effects on the complex pathophysiology of MS.
The research will focus on crucial aspects for MS biology. Specifically, it will be investigated how ozanimod may contrast neurodegenerative mechanisms triggered by both arms of the adaptive immune response (T and B cells) and by their suboptimal regulation in MS. Overall, the project aims at investigating:
AIM1: ozanimod ability to modulate the synaptotoxic effect of T-cells derived from active MS patients in a MS-chimeric ex-vivo model and to identify possible mediators (IRCCS Neuromed-Pozzilli, in collaboration with Synaptic Immunopathology Laboratory Dep. Systems Medicine, Tor Vergata University of Rome). Inflammatory synaptopathy, namely synapse loss and synaptic dysfunction, is emerging as an important hallmark of grey matter pathology in MS and its mouse model experimental autoimmune encephalomyelitis (EAE). In the past years, evidence has been provided of a direct role of T cell, derived from MS patients or EAE mice, in inducing glutamate-mediated excitotoxicity, a prominent form of synaptopathy detected in the MS/EAE brain. Notably, several lines of evidence indicate that limiting glutamate-excitotoxicity is an attractive therapeutic strategy to treat MS.
Recently, the modulatory effects of ozanimod on inflammatory glutamate-mediated excitotoxicity was investigated and the different involvement of sphingosine receptor subtypes (S1P1 and S1P5) were evaluated in the EAE model. Two main results emerged: first, the S1P1/S1P5 modulator ozanimod has central neuroprotective effects likely mediated by an action on microglia cells and infiltrating lymphocytes, resulting in a reduced release of proinflammatory cytokines, the main players of inflammatory synaptopathy. Second, the central delivery of a selective S1P1 modulator showed neuroprotective effects, in terms of both EAE clinical score and inflammatory synaptopathy, suggesting a primary involvement of this receptor subtype in ozanimod- induced neuroprotection also in MS.
In the present project, the MS chimeric ex-vivo model recently developed in Tor Vergata University' lab, will be used. T cells isolated from active relapsing remitting MS patients but not from non-active (naMS) and healthy subject (HS), induced an increase of the spontaneous glutamatergic currents, reminiscent of the alterations induced by EAE T cells.
In this specific aim of the project, the following aspect will be assessed: i) to investigate if ozanimod is able to modulate the synaptotoxic effect of T dell derived from active MS patients in the MS-chimeric ex-vivo model and ii) to identify sphingosine receptor subtypes and iii) soluble molecules potentially involved.
A role for ozanimod in dampening excitotoxic damage caused by synaptotoxic T-cell circulating in the MS brain, independently of a prevention of T cell trafficking, is expected to be revealed.
AIM2: ozanimod ability to reduce the cytokine-mediated breakdown of the BBB and the migration of the here studied immune cells through ex vivo models of BBB (IRCCS Polyclinic Hospital San Martino). B and T lymphocytes, and NK cells are involved in MS pathogenesis (Lassmann, 2019). They differentially use S1P1 and S1P5 receptors to regulate their traffic across secondary lymphoid tissues, and to enter the CNS through the BBB (Sallusto et al., 2012). In turn, these receptors are important in maintaining the integrity and in restoring the function of BBB (Chun 2021).
Modulators of S1P1 and S1P5 receptors are widely used to treat MS, but their mode of action is only partially known due to the complex downstream effects of the combined interactions among receptors localized at the membrane surfaces of immune cells and at the endothelial cells and podocytes of the BBB. These modulating features have been mainly studied for fingolimod, the first drug of this class used in MS, whereas ozanimod's mechanisms of action need in-depth investigations. Indeed, this drug has chemical structure different from that of fingolimod, a binding restricted to S1P1 and S1P5 receptors vs S1P1, S1P3, S1P4 and S1P5 of fingolimod, different pharmacokinetics, and shorter time of elimination half-life (Chun et al., 2021).
The purpose of this specific aim is to evaluate, in ex vivo models of the human BBB exploited through transwell-based systems and organoids, the effects of ozanimod on: i) maintaining of BBB integrity in a context of cytokine-mediated barrier breakdown; ii) impairing the migration of T cells and NK cells across BBB.
The ex-vivo exposure of peripheral blood mononuclear cells (PBMCs) from MS patients to ozanimod is expected to reduce the damage of the BBB mediated by pro-inflammatory cytokines, as well as to mitigate ability of these immune cells across the BBB. PBMCs of patients with NMOSDs will be also used as inflammatory controls, since in these disorders Th17 cells have a major pathogenetic role, together with the BBB-targeting AQP-4 antibodies.
AIM3: ozanimod ability to affect the migration properties of Epstein-Barr virus (EBV) infected B cells in MS (Sant'Andrea Hospital).
In the general population, the memory subset of B lymphocytes, proved to be decreased during therapy with S1P receptors modulators, is the one that selectively harbors EBV as a latently infecting agent. Several studies on EBV genotypes demonstrated an association of specific Epstein- Barr nuclear antigen 2 (EBNA2) gene variants with MS. EBNA2 acts as a transactivator on both viral and cellular gene promoters/enhancers by obligatory interactions with host cell transcription factors. Taking into consideration the complex interplay between EBNA2 and cellular components, it is likely that EBNA2 variants may affect the processes of early infection and participate in the dysregulated virus-host interactions in MS. Also, MS-associated EBNA2 variants seem to interfere with B cell migration and maturation within germinal centers. Despite the presence of EBV infection in the MS brain is controversial, some observations support evidence of an intrathecal reactivation and virus-driven immunopathogenic response in MS. The hypothesis of this specific aim is that ozanimod can have immunomodulatory effects on B cells and EBV infected cells in a MS context. As already mentioned, ozanimod is a potent S1P1R modulator, that inhibits the egress of lymphocytes from lymphoid tissues. B cells and lymphoblastoid cell lines [spontaneously outgrowing (spLCLs) or in vitro infected with the EBV laboratory strain B95.8 (95.8LCLs)], will be used to study how EBV infection affects migration capacity and how this capacity is affected by ozanimod.
Specifically, the following aspect will be investigated: i) the migration properties of B cells, spLCLs and B95.8LCLs from MS patients and age- and sex-matched healthy donors (HD); ii) if ozanimod is able to modulate the migration properties of the above cells from patients and HD.
The knowledge of ozanimod influence on B cells and EBV-infected B cells migration through lymphoid organs and even in the brain, will be importantly improved by this research.
AIM4: ozanimod ability to modulate the number and/or function of regulatory T cells (Treg), a lymphocyte population playing a key role in the control of autoimmune responses (Treg Cell Laboratory, Università degli Studi di Napoli "Federico II", Naples, Italy, receiving blood samples from Neuromed Hospital and Sant'Andrea Hospital; not recruiting unit). Intracellular metabolic pathways are able to control the induction and function of different immune cellular subsets, indeed glycolysis is indispensable for the generation of human iTreg cells from Tconv cells. In addition, a glycolytic defect during the activation of Tconv cells in MS and T1D subjects, was associated with a reduced induction and suppressive function of iTreg cells in these patients suggesting a defective function of iTreg cells during autoimmunity. The effect of ozanimod on the cellular metabolic profile of T lymphocytes and of iTreg cells will be investigated. In particular, this specific aim will evaluate i) the capacity of ozanimod to affect T cell and iTreg cell function/activity (activation, proliferation, suppression, Foxp3 induction) and ii) the metabolic asset of circulating T cell populations (ie. measurement of glycolysis and oxidative phosphorylation) purified from healthy subjects and MS patients.
Ozanimod is expected to be able to control immunometabolism of Tconv and iTreg cells in RRMS patients. This aim will also assess whether ozanimod is able to modify the induction of iTreg cells in healthy controls and RRMS patients.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Patients with RRMS (untreated) | – | Procedure: Peripheral blood withdrawal* Relapsing-remitting MS, as diagnosed by the revised 2010 McDonald Criteria; * EDSS score ≤ 5.5; * Age between 18 and 55 years (exclusive); * no disease modifying therapies for at least 3 months or treatment naïve; * no corticosteroid administration in the previous month; * disease duration <10 years; * Ability to provide written informed consent. |
| Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD) | – | Procedure: Peripheral blood withdrawalMain inclusion criteria of NMOSD patients (Wingerchuk et al., 2015): * Positive test for Aquaporin 4 IgG; * Age between 18 and 55 years (exclusive); * no immunosuppressive therapies for at least 3 months or treatment naïve. * no corticosteroid administration in the previous month * disease duration <10 years * Ability to provide written informed consent |
| Healthy subjects (HD) | – | Procedure: Peripheral blood withdrawal* Age between 18 and 55 years (exclusive), matched by gender, age and ethnicity towards the MS groups. * Ability to provide written informed consent. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- This is a prospective non interventional study with MS patients enrolled within the routinely programmed clinical examinations at the IRCCS NeuromedPozzilli, IRCCS polyclinic hospital San Martino (Genoa, Italy), Sant'Andrea Hospital - University of Rome La Sapienza (Rome, Italy). Study population: Approximately 72 Relapsing-Remitting Multiple Sclerosis (RRMS - naïve or after 3 months wash out from DMT patients; 10 Neuromyelitis Optica Spectrum Disorders patients (NMOSD); 72 healthy subjects (HD) will be recruited from the hospitals involved in the study.
Key inclusion criteria (20 listed)
- Relapsing-remitting MS, as diagnosed by the revised 2010 McDonald Criteria
- EDSS score ≤ 5.5;
- Age between 18 and 55 years (exclusive);
- No disease modifying therapies for at least 3 months or treatment naïve;
- No corticosteroid administration in the previous month;
Key exclusion criteria (3 listed)
- Adverse effects to MRI imaging with i.v. gadolinium;
- Blood count basal alteration;
- Clinically significant medical condition other than MS, including latent infections (e.g. tuberculosis, viral hepatitis, HIV/AIDS) that might confound the results of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Peripheral blood withdrawal25 ml of blood for T cell isolation or 40 ml of blood for B cell isolation will be obtained following informed consent as approved by the ethical committees of the MS centers. | Procedure or surgery | Healthy subjects (HD), Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD), Patients with RRMS (untreated) |
Primary outcome
To evaluate the potential anti-synaptotoxic effect of ozanimod on electrophysiological kinetics in the MS chimeric model
Time frame: 18 months
1.1.1. T cells will be isolated from the peripheral blood of naïve active RRMS patients and will be reated in culture with ozanimod (1000 nM) or vehicle for 24 h. After treatment, T cells will be incubated on corticostriatal slices derived from healthy mice and electrophysiological recording will be performed to measure: • kinetics of the spontaneous synaptic transmission (half width, decay time and rise time, in ms); The same experiments will be performed by using cell treated with S1P1 and S1P5 selective agonists. The primary endpoint will be the comparison of electrophysiological parameters between ozanimod and vehicle conditions, to evaluate a potential beneficial effect of ozanimod on the synaptic alterations induced by MS lymphocytes.
To evaluate the potential anti-synaptotoxic effect of ozanimod on electrophysiological frequency in the MS chimeric model
Time frame: 18 months
1.1.2. T cells will be isolated from the peripheral blood of naïve active RRMS patients and will be reated in culture with ozanimod (1000 nM) or vehicle for 24 h. After treatment, T cells will be incubated on corticostriatal slices derived from healthy mice and electrophysiological recording will be performed to measure: • frequency of the spontaneous synaptic transmission (in Hz); The same experiments will be performed by using cell treated with S1P1 and S1P5 selective agonists. The primary endpoint will be the comparison of electrophysiological parameters between ozanimod and vehicle conditions, to evaluate a potential beneficial effect of ozanimod on the synaptic alterations induced by MS lymphocytes.
To evaluate the potential anti-synaptotoxic effect of ozanimod on electrophysiological amplitude in the MS chimeric model
Time frame: 18 months
1.1.3. T cells will be isolated from the peripheral blood of naïve active RRMS patients and will be reated in culture with ozanimod (1000 nM) or vehicle for 24 h. After treatment, T cells will be incubated on corticostriatal slices derived from healthy mice and electrophysiological recording will be performed to measure: • amplitude of the spontaneous synaptic transmission (in pA). The same experiments will be performed by using cell treated with S1P1 and S1P5 selective agonists. The primary endpoint will be the comparison of electrophysiological parameters between ozanimod and vehicle conditions, to evaluate a potential beneficial effect of ozanimod on the synaptic alterations induced by MS lymphocytes.
To asses the ability of ozanimod to reduce the breakdown of the ex vivo model of BBB (BBB integrity).
Time frame: 18 months
2.1. The impact on the integrity of BBB will be assessed for T and NK cells isolated from naive MS patients, and exposed or not ex-vivo to ozanimod. Differences in the expression of the tight junction proteins as Claudin-5, Occludin, Zonula Occludens-1 (fold change) upon exposure of BBB models to immune cells from MS patients, treated or not ex vivo with ozanimod, will be evaluated. The primary endpoint will be the comparison of BBB integrity, matching the results from ozanimod stimulated vs ozanimod unstimulated cells taken from each patient.
To asses the ability of ozanimod to reduce the cytokine-mediated permeability of the ex vivo model of BBB.
Time frame: 18 months
2.2. The impact on the migration ability across the BBB will be assessed for T and NK cells isolated from naive MS patients, and exposed or not ex-vivo to ozanimod. Differences in the migration across ex vivo models of BBB of immune cells isolated from MS patients after incubation with ozanimod, will be evaluated (dye fluorescencent signal). The primary endpoint will be the comparison of BBB permeability to T and NK cells, matching the results from ozanimod stimulated vs ozanimod unstimulated cells taken from each patient.
To evaluate the migration properties of B cells, spLCLs (with 1.2 and with 1.3 viral alleles) and B95.8LCLs isolated from peripheral blood of (untreated) RRMS and HD.
Time frame: 18 months
3. B cells and LCLs will be cultured in the presence of different drug concentrations and transwell migration assays will be performed to evaluate their ability to migrate through a membrane. At least 5 LCLs and related B cells will be tested for each EBNA2 alleles. Specifically, this aim will investigate: The migration properties of B cells, spLCLs and B95.8LCLs from MS patients and age- and sex-matched HD, and if ozanimod is able to modulate the migration properties of the above cells from patients and HD. The primary endpoint will be the comparison of the migratory capacity (sphingosine- and chemokine-driven) of EBV-infected B cells compared to non-infected cells; whether different viral genotypes modify this capacity; whether and how the above properties differ between patients and controls; whether and how ozanimod affects the above properties.
To evaluate the effect of ozanimod on the proliferation of Treg cells
Time frame: 18 months
4.1. It has been demonstrated that human CD4+CD25- Tconv cells isolated from PBMC of human subjects and activated in vitro in the presence of low-TCR engagement, acquire a suppressive phenotype and generate highly suppressive human iTreg cells. Therefore, in order to evaluate the effect of ozanimod on the induction of iTreg, Tconv cells will be isolated from healthy subjects and RRMS patients and after 36 h culture in the presence of ozanimod or vehicle, activated CD4+CD25- T cells will be FACS-sorted and will be analyzed for their proliferative potential (Ki67 fluorescence). The primary endpoint will be the comparison of iTreg cell proliferation between Tconv cell stimulated in the presence or not of ozanimod.
To evaluate the effect of ozanimod on metabolic asset of Treg cells.
Time frame: 18 months
4.2. After Tconv cells isolation from healthy subjects and RRMS patients and 36 h culture in the presence of ozanimod or vehicle, activated CD4+CD25- T cells will be FACS-sorted and will be analyzed for metabolic asset. The effect of ozanimod on the metabolic asset of iTreg will be evaluated by assessing p-S6 fluorescence. The primary endpoint will be the comparison of iTreg cell metabolic asset between Tconv cell stimulated in the presence or not of ozanimod.
To evaluate the effect of ozanimod on the function of Treg cells.
Time frame: 18 months
4.3. After Tconv cells isolation from healthy subjects and RRMS patients and 36 h culture in the presence of ozanimod or vehicle, activated CD4+CD25- T cells will be FACS-sorted and will be analyzed for their function. The effect of ozanimod on the induction of iTreg will be evaluated by assessing the expression levels of the two major FoxP3 splicing forms, one containing (FoxP3E2) and the other lacking (FoxP3∆2) the exon 2. The primary endpoint will be the comparison of iTreg cell function between Tconv cell stimulated in the presence or not of ozanimod.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2022.
- Background: PubMed 32455907Musella A, Gentile A, Guadalupi L, Rizzo FR, De Vito F, Fresegna D, Bruno A, Dolcetti E, Vanni V, Vitiello L, Bullitta S, Sanna K, Caioli S, Balletta S, Nencini M, Buttari F, Stampanoni Bassi M, Centonze D, Mandolesi G. Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis. Cells. 2020 May 22;9(5):1290. doi: 10.3390/cells9051290.
- Background: PubMed 26414764De Rosa V, Galgani M, Porcellini A, Colamatteo A, Santopaolo M, Zuchegna C, Romano A, De Simone S, Procaccini C, La Rocca C, Carrieri PB, Maniscalco GT, Salvetti M, Buscarinu MC, Franzese A, Mozzillo E, La Cava A, Matarese G. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat Immunol. 2015 Nov;16(11):1174-84. doi: 10.1038/ni.3269. Epub 2015 Sep 28.
- Background: PubMed 25740864Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, Fornasiero A, D'Erchia AM, Buscarinu MC, Agliardi C, Annibali V, Serafini B, Rosicarelli B, Romano S, Angelini DF, Ricigliano VA, Buttari F, Battistini L, Centonze D, Guerini FR, D'Alfonso S, Pesole G, Salvetti M, Ristori G. Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology. 2015 Mar 31;84(13):1362-8. doi: 10.1212/WNL.0000000000001420. Epub 2015 Mar 4.
- Background: PubMed 32503977Agasing AM, Wu Q, Khatri B, Borisow N, Ruprecht K, Brandt AU, Gawde S, Kumar G, Quinn JL, Ko RM, Mao-Draayer Y, Lessard CJ, Paul F, Axtell RC. Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nat Commun. 2020 Jun 5;11(1):2856. doi: 10.1038/s41467-020-16625-7.
- Background: PubMed 23592979Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F, Battistini L. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9(4):e1003220. doi: 10.1371/journal.ppat.1003220. Epub 2013 Apr 11.
- Background: PubMed 29470968Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron. 2018 Feb 21;97(4):742-768. doi: 10.1016/j.neuron.2018.01.021.
- Background: PubMed 30382243Bergmann S, Lawler SE, Qu Y, Fadzen CM, Wolfe JM, Regan MS, Pentelute BL, Agar NYR, Cho CF. Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics. Nat Protoc. 2018 Dec;13(12):2827-2843. doi: 10.1038/s41596-018-0066-x.
- Background: PubMed 19295150Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, Musella A, D'Amelio M, Cavallucci V, Martorana A, Bergamaschi A, Cencioni MT, Diamantini A, Butti E, Comi G, Bernardi G, Cecconi F, Battistini L, Furlan R, Martino G. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci. 2009 Mar 18;29(11):3442-52. doi: 10.1523/JNEUROSCI.5804-08.2009.
- Background: PubMed 27635051Chiara M, Manzari C, Lionetti C, Mechelli R, Anastasiadou E, Chiara Buscarinu M, Ristori G, Salvetti M, Picardi E, D'Erchia AM, Pesole G, Horner DS. Geographic Population Structure in Epstein-Barr Virus Revealed by Comparative Genomics. Genome Biol Evol. 2016 Dec 14;8(11):3284-3291. doi: 10.1093/gbe/evw226.
- Background: PubMed 33289881Chun J, Giovannoni G, Hunter SF. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. Drugs. 2021 Feb;81(2):207-231. doi: 10.1007/s40265-020-01431-8.
- Background: PubMed 18970977Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7.
- Background: PubMed 26250739Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015 Sep 15;15(9):545-58. doi: 10.1038/nri3871. Epub 2015 Aug 7.
- Individual participant dataSharing planned: No
Related trials for Relapsing-Remitting Multiple Sclerosis (RRMS)
Not yet recruiting
Treatment of Memory Retrieval Impairments in MS With HDtDCS to the LIFG in a Placebo Controlled Trial
Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS)
Active, not recruitingPhase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Relapsing-remitting Multiple Sclerosis (RRMS)
RecruitingPhase 2
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
Relapsing-remitting Multiple Sclerosis (RRMS)
RecruitingPhase 3
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
RecruitingPhase 2
Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
Multiple Sclerosis, RRMS
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fabio Buttari, PhD principal investigator
IRCCS Neuromed, Pozzilli, Isernia Italy
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Relapsing-Remitting Multiple Sclerosis (RRMS) and Neuromyelitis Optica, run by Neuromed IRCCS at 3 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Fabio Buttari, PhD (+393384999878, fabio.buttari@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate the potential anti-synaptotoxic effect of ozanimod on electrophysiological kinetics in the MS chimeric model (time frame: 18 months). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05245344, which also lists 32 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2022; AzTrials last refreshed its copy on 8 Nov 2026.